Literature DB >> 17656470

Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone.

Melita M Dvorak1, Cyrille De Joussineau, D Howard Carter, Trairak Pisitkun, Mark A Knepper, Gerardo Gamba, Paul J Kemp, Daniela Riccardi.   

Abstract

Thiazide diuretics are used worldwide as a first-choice drug for patients with uncomplicated hypertension. In addition to their antihypertensive effect, thiazides increase bone mineral density and reduce the prevalence of fractures. Traditionally, these effects have been attributed to increased renal calcium reabsorption that occurs secondary to the inhibition of the thiazide-sensitive sodium chloride cotransporter (NCC) in the distal tubule. The aim of the current study was to determine whether thiazides exert a direct bone-forming effect independent of their renal action. We found that the osteoblasts of human and rat bone also express NCC, suggesting that these bone-forming cells may be an additional target for thiazides. In vitro, NCC protein was virtually absent in proliferating human and fetal rat osteoblasts, whereas its expression dramatically increased during differentiation. Thiazides did not affect osteoblast proliferation, but directly stimulated the production of the osteoblast differentiation markers runt-related transcription factor 2 (runx2) and osteopontin. Using overexpression/knockdown studies in fetal rat calvarial cells, we show that thiazides increase the formation of mineralized nodules, but loop diuretics do not. Overall, our study demonstrates that thiazides directly stimulate osteoblast differentiation and bone mineral formation independent of their effects in the kidney. Therefore, in addition to their use as antihypertensive drugs, our results suggest that thiazides may find a role in the prevention and treatment of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17656470      PMCID: PMC2216427          DOI: 10.1681/ASN.2007030348

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  24 in total

1.  Low-dose thiazide and bone density.

Authors:  Hosam K Kamel
Journal:  Ann Intern Med       Date:  2002-02-05       Impact factor: 25.391

Review 2.  The renal tubular Na-Cl co-transporter (NCCT): a potential genetic link between blood pressure and bone density?

Authors:  D N Cruz
Journal:  Nephrol Dial Transplant       Date:  2001-04       Impact factor: 5.992

3.  Effects of hydrochlorothiazide and furosemide diuretics on human bone marrow stromal osteoprogenitor cells.

Authors:  C H Kim; S W Kim; G S Kim
Journal:  Metabolism       Date:  2000-01       Impact factor: 8.694

4.  Human cortical distal nephron: distribution of electrolyte and water transport pathways.

Authors:  Helena Lagger Biner; Marie-Pierre Arpin-Bott; Johannes Loffing; Xiaoyan Wang; Mark Knepper; Steve C Hebert; Brigitte Kaissling
Journal:  J Am Soc Nephrol       Date:  2002-04       Impact factor: 10.121

5.  Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro.

Authors:  A Lalande; S Roux; M A Denne; E R Stanley; P Schiavi; D Guez; M C De Vernejoul
Journal:  J Bone Miner Res       Date:  2001-02       Impact factor: 6.741

6.  N-Glycosylation at two sites critically alters thiazide binding and activity of the rat thiazide-sensitive Na(+):Cl(-) cotransporter.

Authors:  Robert S Hoover; Esteban Poch; Adriana Monroy; Norma Vázquez; Toshiyuki Nishio; Gerardo Gamba; Steven C Hebert
Journal:  J Am Soc Nephrol       Date:  2003-02       Impact factor: 10.121

7.  changes in serum and urinary calcium during treatment with hydrochlorothiazide: studies on mechanisms.

Authors:  A S Brickman; S G Massry; J W Coburn
Journal:  J Clin Invest       Date:  1972-04       Impact factor: 14.808

8.  Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones.

Authors:  Melita M Dvorak; Ashia Siddiqua; Donald T Ward; D Howard Carter; Sarah L Dallas; Edward F Nemeth; Daniela Riccardi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

9.  Idiopathic hypercalciuria: hydrochlorothiazide decrease urinary calcium without altered renal response to parathyroid hormone.

Authors:  C J Van Den Berg; R M Tucker; T P Dousa
Journal:  J Clin Endocrinol Metab       Date:  1982-07       Impact factor: 5.958

10.  Thiazide effect on the mineral content of bone.

Authors:  R D Wasnich; R J Benfante; K Yano; L Heilbrun; J M Vogel
Journal:  N Engl J Med       Date:  1983-08-11       Impact factor: 91.245

View more
  36 in total

1.  Osteoblast extracellular Ca2+ -sensing receptor regulates bone development, mineralization, and turnover.

Authors:  Melita M Dvorak-Ewell; Tsui-Hua Chen; Nathan Liang; Caitlin Garvey; Betty Liu; Chialing Tu; Wenhan Chang; Daniel D Bikle; Dolores M Shoback
Journal:  J Bone Miner Res       Date:  2011-12       Impact factor: 6.741

Review 2.  The thiazide-sensitive Na+-Cl- cotransporter: molecular biology, functional properties, and regulation by WNKs.

Authors:  Gerardo Gamba
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-27

Review 3.  Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia.

Authors:  Sirirat Reungjui; Thongchai Pratipanawatr; Richard J Johnson; Takahiko Nakagawa
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-09       Impact factor: 2.894

Review 4.  The sodium chloride cotransporter SLC12A3: new roles in sodium, potassium, and blood pressure regulation.

Authors:  Arthur D Moes; Nils van der Lubbe; Robert Zietse; Johannes Loffing; Ewout J Hoorn
Journal:  Pflugers Arch       Date:  2013-12-06       Impact factor: 3.657

Review 5.  Thiazide effects and adverse effects: insights from molecular genetics.

Authors:  David H Ellison; Johannes Loffing
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

Review 6.  CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets.

Authors:  Rosilene Motta Elias; Maria Aparecida Dalboni; Ana Carolina E Coelho; Rosa M A Moysés
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 7.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

Review 8.  Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.

Authors:  Mahua Ghosh; Sumit R Majumdar
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

Review 9.  The long-term complications of the inherited tubulopathies: an adult perspective.

Authors:  Maryam Khosravi; Stephen B Walsh
Journal:  Pediatr Nephrol       Date:  2014-02-25       Impact factor: 3.714

10.  The relation between bone and stone formation.

Authors:  Nancy S Krieger; David A Bushinsky
Journal:  Calcif Tissue Int       Date:  2012-12-18       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.